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Abstract
Background: MicroRNAs (miRNAs) are a new class of naturally occurring, small, non-coding RNAs that regulate
protein-coding mRNAs by causing mRNA degradation or repressing translation. The roles of miRNAs in lineage
determination and proliferation, as well as the localization of several miRNA genes at sites of translocation
breakpoints or deletions, have led to speculation that miRNAs could be important factors in the development or
maintenance of the neoplastic state.
Results: We showed that miR-9 was downregulated in human gastric adenocarcinoma. Overexpression of miR-9
suppressed the growth of human gastric adenocarcinoma cell line MGC803 cell as well as xenograft tumors
derived from them in SCID mice. Bioinformatics analysis indicated a putative miR-9 binding site in the 3’-
untranslated region (3’UTR) of the tumor-related gene NF-B1 mRNA. In an EGFP reporter system, overexpression
of miR-9 downregulated EGFP intensity, and mutation of the miR-9 binding site abolished the effect of miR-9 on
EGFP intensity. Furthermore, both the NF-B1 mRNA and protein levels were affected by miR-9. Finally, knockdown
of NF-B1 inhibited MGC803 cell growth in a time-dependent manner, while ectopic expression of NF-B1 could
rescue MGC803 cell from growth inhibition caused by miR-9.
Conclusion: These findings indicate that miR-9 targets NF-B1 and regulates gastric cancer cell growth, suggesting
that miR-9 shows tumor suppressive activity in human gastric cancer pathogenesis.
Background
In recent years, a new class of naturally occurring, small,
non-coding RNAs called microRNAs (miRNAs) have
been discovered in plants and animals [1-3]. Unlike pro-
tein-coding mRNAs, miRNAs are first transcribed as
long primary transcripts in the nucleus, and then
cleaved to produce stem-loop-structured precursor
molecules (pre-miRNAs) by Drosha [4]. Pre-miRNAs
are then exported to the cytoplasm, where the RNase III
enzyme Dicer further processes them into mature miR-
NAs (~22 nucleotides). Mature miRNAs negatively reg-
ulate gene expression at the post-transcriptional level.
Through specific targeting of the 3’-untranslationed
regions (3’UTR) of multicellular eukaryotic mRNAs,
miRNAs downregulate gene expression by degrading
target mRNAs or repressing their translation [5,6]. Since
miRNAs bind the 3’UTR of target genes through partial
sequence homology, miRNAs could control as much as
30% of all protein-coding genes [7].
An accumulating body of evidence has revealed criti-
cal functions for miRNAs in diverse biological processes,
such as proliferation, apoptosis, and cell differentiation
[8,9]. Thus, deregulation of miRNA expression may lead
to a variety of disorders including many types of cancers
[10]. Previous studies have identified cancer-specific
miRNAs in many kinds of cancers, including ovarian
cancer [11], lung cancer [12], breast cancer [13], hepato-
cellular carcinoma [14], and brain cancer [15,16]. In
addition, miRNA genes are frequently located near
genomic breakpoints [16] or are affected by copy num-
ber alterations [17]. Also, factors involved in miRNA
biosynthesis may be dysregulated in human tumors
[18,19]. Furthermore, a recent study described aberrant
hypermethylation as a mechanism for miRNA genes
including miR-9 inactivation and downexpression in
human breast cancer [20]. Meanwhile, another study
provided evidence that miR-9 acts as a tumor suppres-
sor gene in recurrent ovarian cancer [21].
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any medium, provided the original work is properly cited.Gastric cancer is the second most common cause of
cancer death in the world [22], and adenocarcinoma
is the most common type of gastric cancer. In this
study, we detected differential expression of miR-9 in
human gastric adenocarcinoma and adjacent normal
tissues through quantitative RT-PCR, and hypothe-
sized miR-9 as a tumor suppressor. Consistent with
this hypothesis, we observedt h a to v e r e x p r e s s i o no f
miR-9 inhibited the growth of the gastric adenocarci-
noma cell line MGC803 in vitro and in vivo.S u b s e -
quently, we predicted and confirmed that the tumor-
related transcription factor NF-B1 was a direct target
of miR-9 and was negatively regulated by miR-9 at the
post-transcriptional level. Finally, in MGC803 cells,
suppression of NF-B1 expression by specific small
interfering RNA (siRNA) could also inhibit MGC803
cell growth, while ectopic expression of NF-B1 could
rescue MGC803 cell from growth inhibition caused by
miR-9.
Methods
Clinical Specimen and RNA Isolation
Nine pairs of gastric samples, including nine human gas-
tric adenocarcinoma tissue samples and nine matched
normal gastric tissue samples, were obtained from the
Tumor Bank Facility of Tianjin Medical University Can-
cer Institute and Hospital and the National Foundation
of Cancer Research (TBF of TMUCIH & NFCR) with
patients’ informed consent. The category of gastric sam-
ples was confirmed by pathological analysis. The large
RNA and small RNA of tissue samples were isolated
using mirVana™ miRNA Isolation Kit (Ambion) accord-
ing to the manufacturer’s instructions.
Cell Culture and Transfection
The human gastric adenocarcinoma cell line MGC803
was grown in RPMI 1640 (GIBCO) supplemented with
10% fetal bovine serum, 100 IU/ml of penicillin and 100
μg/ml of streptomycin, incubated at 37°C in a humidi-
fied chamber supplemented with 5% CO2. Transfection
was performed with Lipofectamine 2000 Reagent (Invi-
trogen) following the manufacturer’s protocol. Spiked
RFP-expressing vector was used to monitor transfection
efficiency.
Construction of Expression Vectors
To construct the pcDNA3/pri-miR-9 (pri-miR-9)
expressing vector, we first amplified a 386-bp DNA frag-
ment carrying pri-miR-9 from genomic DNA using the
following PCR primers: miR-9-sense, 5’-CGGAG
ATCTTTTCTCTCTTCACCCTC-3’,a n dm i R - 9 - a n t i -
sense, 5’-CAAGAATTCGCCCGAACCAGTGAG-3’. The
amplified fragment was cloned into the pcDNA3.1 (+) at
the BglII and EcoRI sites.
To construct the pSilencer/si-NF-B1 (si-NF-B1)
vector, a 70-bp double-strand fragment was obtained via
annealing reaction using two single-strands designed by
Deqor (at http://cluster-1.mpi-cbg.de/Deqor/deqor.
html): NF-B1-Top, 5’-GATCCCGCCTGAACAAATGT
TTCATTTGGTCAAGAGCCAAATGAAACATTTGTT
CAGGCTTTTTTGGAAA -3’;a n dN F - B1-Bot, 5’-AGC
TTTTCCAAAAAAGCCTGAACAAATGTTTCATTT
GGCTCTTGACCAAATGAAACATTTGTTCAGGCGG
-3’. The fragment was then cloned into pSilencer 2.1 at
the BamHI and Hind III sites.
To construct the NF-B1 ectopic expression vector,
the whole coding sequence of NF-B1 without the
3’UTR was amplified by PCR from cDNA library of
MGC803 cells. The PCR primers were as follows: NF-
B1-sense, 5’-CGGAATTCACCATGGCAGAAGATG
ATCC -3’;a n dN F - B1-antisense, 5’-GTCAGCTCGAG
AAATTTTGCCTTCTAGAGGTC -3’.T h ea m p l i f i e d
f r a g m e n tw a sc l o n e di n t ot h ep c D N A 3 . 1( + )a tt h e
EcoRI and XhoI sites.
Cell Proliferation Assay
Cells were seeded in 96-well plate at 4 000 cells per well
the day before transfection. The cells were transfected
with pri-miR-9 or control vector at a final concentration
o f5n g / μl as described above. To detect the dose-
dependent effects, we gradually increased concentration
of pri-miR-9 from 0 ng/μlt o1 5n g / μl. To examine the
time-dependent effects of si-NF-B1 on MGC803 cells,
MTT assay was used to measure the viable, proliferating
cells at 24, 48, and 72 h after transfection. The absor-
bance at 570 nm was measured using a μQuant Univer-
sal Microplate Spectrophotometer (Bio-tek Instruments).
Colony Formation Assay
After transfection, cells were counted and seeded in 12-
well plates (in triplicate) at 100 cells per well. Fresh cul-
ture medium was replaced every 3 days. Colonies were
counted only if they contained more than 50 cells, and
the number of colonies was counted from the 6th day
after seeding and then the cells were stained using crys-
tal violet. The rate of colony formation was calculated
with the equation: colony formation rate = (number of
colonies/number of seeded cells) ×100%.
In vivo Tumor Xenograft Studies
To establish the stable miR-9-overexpression cell line and
the control cell line, MGC803 cells were transfected with
pcDNA3/pri-miR-9 (pri-miR-9) or pcDNA3 (control), fol-
lowed by selection for 20-30 days in complete medium
supplemented with 800 μg/ml of G418 (Invitrogen). Single
colonies were picked and amplified, and the expression
level of miR-9 was detected by real-time RT-PCR. The
stable miR-9-overexpression MGC803 cells or control
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6 cells per site bilaterally
on the axillary fossae of female athymic nude mice aged 6-
8 weeks. Tumor size was monitored by measuring the
length and width with calipers, and volumes were calcu-
lated with the formula: (L × W 2) × 0.5, where L is the
length and W is the width of each tumor. The mice used
in this experiment were maintained under specific patho-
gen-free conditions and handled in accordance with NIH
Animal Care and Use Committee regulations.
MiRNA Target Prediction
MiRNA predicted targets were predicted using the algo-
rithms TargetScan, PicTar, and miRBase Targets. To
identify the genes commonly predicted by the three dif-
ferent algorithms, results of predicted targets were inter-
sected using MatchMiner.
Fluorescent Reporter Assay
The EGFP expression vector pcDNA3/EGFP was con-
structed as previously described [23]. The 3’-untranslated
region of NF-B1 mRNA containing the miR-9 binding
site was amplified by PCR using the following primers: NF-
B1 sense, 5’-CGCGGATCCTCAACAAAATGCCC
CATG-3’;a n dN F - B1 antisense, 5’-CGGAATTCAGTT
AAATCGAGAATGATTCAGGCG-3’. The amplified frag-
ment was cloned into pcDNA3/EGFP at BamHI and EcoRI
sites at downstream of the EGFP coding region. Also, four
nucleotides at the miR-9 seed sequence binding site of the
NF-B1 3’UTR were deleted using PCR side-directed
mutagenesis assay. The two additional primers used in the
mutation were as follows: NF-B1 MS, 5’-CCACACCGTG-
TAACAACCCTAAAATTCCAC-3’; and NF-B1 MA, 5’-
GGAATTTTAGGGTTGTTAC ACGGTGTGG-3’.T h e
fragment of NF-B1 3’UTR mutant was similarly cloned
into the pcDNA3/EGFP at the same sites.
MGC803 cells were transfected with pri-miR-9 or
control vector pcDNA3 in 24-well plates, and then with
the reporter vector pcDNA3/EGFP- NF-B1 3’UTR or
pcDNA3/EGFP- NF-B1 3’UTRmut on the next day.
The vector pDsRed2-N1 (Clontech) expressing RFP was
spiked in and used for normalization. The intensities of
EGFP and RFP fluorescence were detected with Fluores-
cence Spectrophotometer F-4500 (HITACHI).
Quantitative RT-PCR
To detect the relative level of NF-B1 transcript, real-
time RT-PCR was performed. Briefly, a cDNA library
was generated through reverse transcription using M-
MLV reverse transcriptase (Promega) with 2 μgo ft h e
large RNA extracted from gastric tissue samples or
MGC803 cells. The cDNA was used for the amplifica-
tion of NF-B1 gene and the b-actin gene was used as
an endogenous control for the PCR reaction. PCR was
performed under the following conditions: 94°C for 4
min followed by 40 cycles of 94°C for 1 min, 56°C for 1
min, 72°C for 1 min. PCR primers were: NF-B1 sense
and NF-B1 antisense were as above; b-actin sense, 5’-C
GTGACATTAAGGAGAAGCTG-3’;a n db-actin anti-
sense, 5’-CTAGAAGCATTTGCGGTGGAC-3’.
To detect the mature miRNA level, stem-loop RT-PCR
assay was performed [24]. Briefly, 2 μgo fs m a l lR N Aw a s
reverse transcribed to cDNA using M-MLV reverse tran-
scriptase (Promega) with the following primers: miR-9-
RT, 5’-GTCGTATCCAGTGCAGGGTCCGAGGTGC
ACTGGATACGACTCATACAG-3’; and U6-RT, 5’-GT
CGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG
GATACGACAAAATATGGAAC-3’, which can fold to a
stem-loop structure. The cDNA was used for the amplifi-
cation of mature miR-9 and an endogenous control U6
snRNA for all PCR reactions. PCR primers were: miR-9-
Fwd, 5’-GCCCGCTCTTTGGTTATCTAG-3’;U 6 - F w d ,
5’-TGCGGGTGCTCGCTTCGGCAGC-3’, and a univer-
sal downstream primer Reverse, 5’-CCAGTGCAGGG
TCCGAGGT-3’. PCR cycles were as follows: 94°C for 4
min, followed by 40 cycles of 94°C for 30 s, 50°C for 30 s,
72°C for 40 s. SYBR Premix Ex Taq™ Kit (TaKaRa) was
used following the manufacturer’s instructions, and the
real-time PCR was performed and analyzed by 7300 Real-
Time PCR system (ABI). All primers were purchased
from AuGCT Inc.
Western Blot
MGC803 cells were transfected and lysed 48 h later
with RIPA lysis buffer and proteins were harvested. All
proteins were resolved on 10% SDS denatured polya-
crylamide gel and then transferred onto a nitrocellu-
lose membrane. Membranes were incubated with anti-
NF-B1 antibody or anti-GAPDH antibody with blotto
overnight at 4°C. The membranes were washed and
incubated with horseradish peroxidase (HRP) conju-
gated secondary antibody. Protein expression was
assessed by enhanced chemiluminescence and exposure
to chemiluminescent film. Lab Works™ Image Acquisi-
tion and Analysis Software (UVP) was used to quantify
band intensities. Antibodies were purchased from
Tianjin Saier Biotech and Sigma-Aldrich.
Statistical Analysis
Data are expressed as means ± standard deviation (SD),
and P ≦ 0.05 is considered as statistically significant by
Students-Newman-Keuls test.
Results
Quantitative Analysis of miR-9 Expression in Human
Gastric Adenocarcinoma
To test the expression of miR-9 in human gastric adeno-
carcinoma and adjacent normal tissues, real-time RT-PCR
assay was performed in nine pairs of gastric tissue samples.
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and significantly lower in gastric adenocarcinoma tissues
than in matched normal gastric tissues (figure 1).
Suppression of Gastric Adenocarcinoma Cell Proliferation
by Overexpression of miR-9 in vitro
To determine the role of miR-9 in tumor cell prolifera-
tion, a miR-9 overexpression vector, pcDNA3/pri-miR-9
(pri-miR-9), was constructed. The validity of miR-9
ectopic expression was confirmed by quantitative RT-
PCR, which revealed a 13-fold increase of miR-9 expres-
sion in pri-miR-9-transfected cells than in the control
group (figure 2A). To test the effects of miR-9 overex-
pression on MGC803 cell proliferation, we investigated
cell growth by MTT assay and found that pri-miR-9
could reduce MGC803 cell growth (figure 2B). Also, this
effect showed a dose-dependent manner. At the concen-
tration of 2.5 ng/μla n d1 5n g / μl of pri-miR-9 plasmid,
cell growth was inhibited by 15% and 45%, respectively
(figure 2C). To further confirm the effect of miR-9 over-
expression on the growth of gastric cancer cells, colony
formation assay was performed. The colony formation
rate of MGC803 cells transfected with pri-miR-9 was
significantly lower than the control group (figure 2D).
These results indicated that overexpression of miR-9
showed an anti-proliferative effect.
Overexpression of miR-9 Inhibits Xenograft Tumor
Growth in vivo
To further determine whether miR-9 is involved in
tumorigenesis, we established a stable miR-9-overex-
pression cell line as well as a control cell line. Cells of
either line were injected into the axillary fossa of SCID
mice, and the tumor growth activity was measured.
Tumors derived from pri-miR-9-treated MGC803 cells
grew substantially slower compared with the control
group during the whole tumor growth period (figure
3B). When tumors were harvested, the average volume
of tumors derived from the pri-miR-9 group was only
half of that in the control group (figures 3A &3C).
These results were consistent with the effects of miR-9
overexpression in vitro and strongly suggested that
miR-9 could inhibit gastric cancer cell growth.
NF-B1 is a Candidate Target Gene of miR-9
MiRNAs can function as tumor suppressors or onco-
genes, depending on whether they specifically target
oncogenes or tumor suppressor genes [25-27]. Tumor
suppressive miRNAs, such as miR-9, are usually under-
expressed in tumors and may fail to control some of the
oncogenic genes. Although underexpression of miR-9 in
some types of tumors suggested its role in cancer devel-
opment, the underlying mechanism is still unclear
because little is known of miR-9 targets. Therefore,
identification of miR-9-regulated targets is a necessary
step to understand miR-9 functions. We used a three-
step consequential approach to identify miR-9 target
genes. First, target genes were predicted by bioinfor-
matics analysis; second, target genes were validated by
fluorescent reporter assay; and finally, the correlation of
miRNA expression and target protein expression were
detected to confirm the specific miRNA:mRNA interac-
tions. The target genes of miR-9 were predicted using
three programs, known as PicTar, TargetScan, and miR-
Base Targets. Of the predicted target genes, the onco-
gene NF-B1, whose mRNA 3’UTR contained a putative
binding site of miR-9, was identified. This analysis is
consistent with the model in which tumor suppressor
miRNAs inhibit tumor development by targeting and
negatively regulating oncogenes.
Figure 1 Identification of differential expression of miR-9 in gastric tissues. The expression level of miR-9 in the nine pairs of gastric
adenocarcinoma tissues (Ca) and matched normal tissues (N) was detected by quantitative RT-PCR. U6 snRNA was regarded as an endogenous
normalizer and the relative miR-9 expression level of the nine pairs of gastric tissues as well as the combined result (mean ± SD) is shown (*P <
0.05).
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The mRNA 3’UTR of candidate miR-9 target gene NF-
B1 carries a putative miR-9 binding site (figure 4A). To
confirm that this site was responsible for the negative reg-
u l a t i o nb ym i R - 9 ,w ec l o n e dt h ep u t a t i v e3 ’UTR binding
site into the downstream of an enhanced green fluores-
cence protein (EGFP) reporter gene (EGFP-NF-B1
3’UTR) and co-transfected this vector with pri-miR-9 or
the control vector into MGC803 cells. The intensity of
EGFP fluorescence of cells transfected with pri-miR-9 was
decreased for about 1.7-fold, which was a statistically sig-
nificant reduction compared with the control group (figure
4C). To further determine the function of the miR-9 bind-
ing site, we constructed another EGFP reporter vector
containing the NF-B1 3’UTR but with a mutated miR-9
binding site (figure 4B). As a result, pri-miR-9 had no
effect on the intensity of EGFP fluorescence in this 3’UTR
mutant vector (figure 4C), highlighting the importance of
this miR-9 binding site. These results suggested that NF-
B 1i sad i r e c tt a r g e to fm i R - 9 .
MiR-9 Negatively Regulates NF-B1 at the Post-
Transcriptional Level
Translational repression is regarded as a major mechan-
ism for miRNA regulation of target gene expression [28].
To determine whether miR-9 suppresses endogenous
NF-B1 through translational repression, MGC803 cells
were transfected with pri-miR-9 and the expression of
NF-B1 protein was examined by Western blot. It was
shown that the amount of NF-B1 protein was decreased
after overexpression of miR-9 (figure 4D), suggesting that
miR-9 negatively regulates endogenous NF-B1 protein
expression through translational repression mechanism.
Furthermore, overexpression of miR-9 in MGC803 cells
Figure 2 Overexpression of miR-9 suppresses tumor cell growth in vitro. (A) In pcDNA3/pri-miR-9 transfected MGC803 cells, the mature
miR-9 level was significantly increased. (B) MGC803 cells were transfected with pri-miR-9, control vector or pri-miR-9 with pcDNA3/NF-B1, and
cell growth activity was determined at 72 h post-transfection by MTT assay. Values are means ± SD of three duplications and the relative cell
growth activity is shown (*P < 0.05). (C) MGC803 cells were transfected with gradually increasing concentrations of pri-miR-9 from 0 ng/μlt o1 5
ng/μl (final concentration) and the dose-dependent anti-proliferative effects were detected by MTT assay. (D) Cell independent growth activity
was detected by colony formation assay. MGC803 cells were transfected with pri-miR-9, control vector or pri-miR-9 with pcDNA3/NF-B1, and
then seeded in 12-well plates. The number of colonies was counted from the 6th day after seeding. The colony formation rate was calculated
and is shown. (E) The validity of NF-B1 ectopic expression vector pcDNA3/NF-B1 was confirmed by Western blot assay. MGC803 cells were
transfected with pri-miR-9 as well as pcDNA3/NF-B1 or control vector. The NF-B1 protein level was detected by Western blot assay. GAPDH
protein was regarded as endogenous normalizer and the relative NF-B1 protein quantity is shown.
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(figure 4E). In the nine pairs of gastric tissues, the NF-
B1 mRNA level showed a predominant up-regulation in
gastric cancer tissues (figure 5). These data suggested
that miR-9 negatively regulate the expression of NF-B1
through mRNA cleavage mechanism.
NF-B1 Promotes Cell Proliferation and Independent
Growth in vitro
Previous studies have shown that the up-regulation of
NF-B1 is an important feature of many transformed
cells, and that NF-B1 functions as an oncogene.
Accordingly, we detected whether NF-B1 affects
MGC803 cell growth. We constructed the pSilencer/si-
NF-B1 (si-NF-B1) plasmid and confirmed that the
expression of NF-B1 protein was effectively sup-
pressed by the siRNA expression vector (figures 6A).
Then, the effect of NF-B1 knockdown on cell growth
was evaluated by MTT assay. As a result, suppression
of NF-B1 decreased cell growth in a time-dependent
manner. At 72 h after transfection, we observed that
cells transfected with the NF-B1 knockdown vector
grew more slowly than the control group (figure 6B).
Also, the colony formation rate of the cells transfected
with si-NF-B1 vector was markedly lower than the
control group (figures 6C &6D). Moreover, ectopic
expression of NF-B1 could rescue MGC803 cell from
growth inhibition caused by miR-9, both in MTT assay
(figure 2B) and colony formation assay (figure 2D).
T h ev a l i d i t yo fp c D N A 3 / N F - B1 vector was confirmed
by Western blot assay (figure 2E). These data, consis-
tent with the previous findings [29], provided further
evidence that NF-B1 is an oncogene. The oncogenic
role of NF-B1 in gastric cancer may explain why
overexpression of miR-9 can inhibit gastric cancer cell
growth.
Discussion
In the last few years, several studies have shown the dys-
regulation of miRNAs in various types of cancers
[30-32]. Identification of cancer-specific miRNAs and
their targets is critical for understanding their role in
tumorigenesis and may be important for defining novel
therapeutic targets [33-35]. Here, we focused on the role
of miR-9 in the pathogenesis of human gastric adeno-
carcinoma. First, we examined miR-9 expression in gas-
tric adenocarcinoma and matched normal gastric tissues
by real-time RT-PCR assay as previously described [24].
This method uses a stem-loop reverse transcription pri-
mer and specially designed PCR primers to ensure the
specificity of miRNA amplification. Meanwhile, U6
snRNA was also detected for normalization of
Figure 3 Suppression of growth activity of xenograft gastric adenocarcinoma derived from MGC803 cells in SCID mice by
overexpression of miR-9. (A) The graphs show the differences between tumor volume in pri-miR-9 group and control group. (B) Tumor
volume was measured after injection of MGC803 cells stably expressing pri-miR-9, and the tumor volume growth curve was drafted. (C) The
difference of tumor volume between the pri-miR-9 group and control group was statistically significant (*P < 0.05).
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from a total of nine pairs of matched advanced gastric
adenocarcinoma tissue samples, the level of miR-9 was
downregulated in tumor tissues compared to the
matched normal tissues.
Several studies on the role of miR-9 deregulation in
human oncogenesis have been reported. The aberrant
hypermethylation study was done using the compre-
hensive methylation analysis approach, with breast
cancer, normal breast tissues, and breast cancer cell
lines as references. They found that the epigenetic
inactivation of miR-9-1 in human breast cancer was
due to aberrant hypermethylation, and found a strong
correlation between hypermethylation of miR-9-1 and
concomitant downregulation [20]. Interestingly, taking
advantage of miRNA expression analysis and real-time
TaqMan PCR, it was also found that miR-9 expression
was decreased in recurrent ovarian cancer tissues com-
pared to primary cancer tissues [21]. In addition, miR-
9, miR-148a, and miR-34b/c were also underwent spe-
cific hypermethylation-associated silencing in cancer
cells compared with normal tissues [36]. Hence, the
Figure 4 NF-B1 is a direct target of miR-9. (A) The predicted miR-9 binding site on NF-B1 mRNA 3’UTR is shown. (B) Deletion mutation at
the miR-9 “seed region” binding site on the NF-B1 mRNA 3’UTR is shown. Four nucleotides were deleted on the mutated 3’UTR. (C) MGC803
cells were transfected with the wild type of EGFP- NF-B1 3’UTR (Wt. UTR) or mutated EGFP- NF-B1 3’UTR (Mut. UTR) reporter vector as well as
pri-miR-9 or control vector. Although pri-miR-9 suppressed the EGFP fluorescence intensity of EGFP- NF-B1 3’UTR, mutation of the miR-9
binding site abolished the effect of miR-9 on the EGFP fluorescent intensity. (D) MGC803 cells were transfected with pri-miR-9 or control vector,
and the NF-B1 protein (P105 and P50) expression level was evaluated by Western blot. GAPDH protein was regarded as endogenous
normalizer and the relative NF-B1 protein quantity is shown. (E) MGC803 cells were transfected with pri-miR-9 or control vector, and expression
of NF-B1 mRNA was measured by quantitative RT-PCR. b-actin mRNA was regarded as an endogenous normalizer and the relative NF-B1
mRNA expression level is shown. (*P < 0.05)
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ferent types of cancer tissues and cells suggests that
downregulation of miR-9 might play an important role
in oncogenesis.
It has been presumed that miRNAs suppressed in can-
cers may normally function as tumor suppressor genes.
Therefore, we hypothesized that miR-9 is a growth inhibi-
tion factor in human gastric adenocarcinoma. Since miR-9
expression is decreased in cancer tissues, we expected that
overexpression of miR-9 would result in the arrest of cell
growth. Using the MTT assay, we found that MGC803
cells transfected with the miR-9 overexpression vector
(pri-miR-9) exhibited decreased growth compared to con-
trol cells. We also found that the anti-proliferative activity
of pri-miR-9 transfection was dose-dependent. Cell inde-
pendent growth activity, which is inconspicuous in normal
cells, is a typical characteristic of malignant transformed
cells. In colony formation assay, we observed that the col-
ony formation activity of MGC803 cells transfected with
pri-miR-9 was significantly inhibited. Furthermore, we
Figure 5 Identification of differential expression of NF-B1 in gastric tissues. The expression level of NF-B1 in the nine pairs of gastric
adenocarcinoma tissues (Ca) and matched normal tissues (N) was detected by quantitative RT-PCR. b-actin mRNA was regarded as an
endogenous normalizer and the relative NF-B1 quantities of the nine pairs of gastric tissues as well as the combined result (mean ± SD) is
shown (*P < 0.05).
Figure 6 Knockdown of NF-B1 suppresses cell growth and colony formation. (A) In pSilencer/si-NF-B1 (si-NF-B1) transfected MGC803
cells, the expression level of NF-B1 protein was significantly decreased. (B) MGC803 cells were transfected with si-NF-B1 or control vector.
Relative cell growth activity was determined by MTT assay at the indicated times. Values are means ± SD of three duplications and the relative
cell growth activity is shown (*P < 0.05). (C) Cell independent growth activity was detected by colony formation assay. MGC803 cells were
transfected with si-NF-B1 or control vector at a final concentration of 5 ng/μl (final concentration) and then seeded in 12-well plates. The
number of colonies was counted on the 9th day after seeding. The colony formation rate was calculated and is shown (**P < 0.01). (D) The cells
of colony formation assay were stained by crystal violet and the representative pictures of colonies are shown.
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MGC803 cells transfected with pri-miR-9 in SCID mice
was lower than that of control tumors. Hence, these
results indicate that gastric adenocarcinoma cells trans-
fected with pri-miR-9 showed deletion of malignant phe-
notypes, suggesting a role for miR-9 in the growth
suppression of cancer cells.
It was unclear as to how miR-9 affects cell growth and
proliferation, because little is known about the physiolo-
gic targets of miR-9. Although bioinformatic tools may
help to reveal putative mRNA targets of miRNAs,
experimental procedures are required for their valida-
tion. Only a few studies have identified oncogenes
whose level of expression is regulated by miRNAs. For
instance, members of the let-7 miRNA family can nega-
tively regulate all three members of the RAS oncogene
family [27], and miR-15a/miR-16-1 can target and regu-
late BCL2 in B-cell CLL cells [25]. These findings sup-
port the idea that miRNA dysregulation may be
involved in cancer pathogenesis. In this study, we show
that miR-9 targets the NF-B1 mRNA, thus revealing a
potential mechanism associated with gastric
tumorigenesis.
Experimental evidence indicated that NF-B1 is a tar-
get of miR-9. First, the ability of miR-9 to regulate NF-
B1 expression is likely direct, because it binds to the
3’UTR of NF-B1 mRNA with complementarity to the
miR-9 seed region. Second, the EGFP fluorescence
intensity of EGFP- NF-B1-UTR was specifically respon-
sive to miR-9 overexpression. Third, mutation of the
miR-9 binding site abolished the effect of miR-9 on the
regulation of EGFP fluorescence intensity. Fourth, we
observed an inverse correlation between the expression
of miR-9 and NF-B1 in gastric adenocarcinoma tissues.
Finally, endogenous NF-B1 expression, both mRNA
and protein, is decreased in pri-miR-9-treated MGC803
cells, suggesting that miR-9 may regulate NF-B1 pro-
tein expression by inducing mRNA degradation and/or
translational suppression.
The NF-B1 gene encodes a 105 kD protein, which can
undergo cotranslational processing by the 26S proteasome
to produce the 50 kD protein. In fact, NF-B1 is a mem-
ber of the Rel/NF-B transcription factor family, which
plays important roles in the regulation of immune
responses, embryo and cell lineage development, cell-cycle
progression, inflammation, and oncogenesis [37-39].
Moreover, the positive rate of NF-B1 in diffuse large B-
cell lymphoma (DLBCL) was 63% (39/62), but none was
expressed in reactive proliferation lymph node. However,
NF-B1 can positively regulate the expression of VEGF in
DLBCL [40]. In addition, suppression of NF-B expression
can downregulate the expression of VEGF, thereby inhibit-
ing the invasion and metastasis of tumors [41]. In this
study, knockdown of NF-B1 suppressed the growth of
MGC803 cells, which was consistent with the results of
miR-9 overexpression. Ectopic expression of NF-B1
could also rescue MGC803 cells from growth inhibition
caused by miR-9. However, the underlying mechanisms by
which NF-B1 affects gastric cancer cell growth remain to
be established.
Conclusions
In summary, we show that miR-9 expression is
decreased in gastric adenocarcinoma tissues and that
pri-miR-9 inhibits gastric cancer cell growth in vitro and
in vivo. Furthermore, the expression of NF-B1 can be
negatively regulated by miR-9. This study extends our
knowledge about the regulation of NF-B1, a tumor-
related protein. Thus, in addition to epigenetic regula-
tion, NF-B1 is also regulated at the post-transcriptional
level by miRNA. It may suggest that miR-9 plays impor-
tant roles in diverse biological processes by regulating
NF-B1.
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